Insider Selling: Inspire Medical Systems, Inc. (NYSE:INSP) Director Sells $176,000.00 in Stock

Inspire Medical Systems, Inc. (NYSE:INSP) Director Shawn Mccormick sold 800 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Inspire Medical Systems Stock Up 0.2 %

Shares of Inspire Medical Systems stock opened at $203.99 on Friday. The firm has a market cap of $6.08 billion, a PE ratio of -370.89 and a beta of 1.33. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40. The business’s fifty day simple moving average is $168.99 and its 200-day simple moving average is $181.09.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. Inspire Medical Systems had a net margin of 0.85% and a return on equity of 1.03%. The company had revenue of $195.89 million for the quarter, compared to analysts’ expectations of $189.08 million. During the same quarter in the prior year, the company posted ($0.41) earnings per share. Inspire Medical Systems’s revenue for the quarter was up 29.6% compared to the same quarter last year. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current year.

Analyst Ratings Changes

INSP has been the subject of several research reports. Robert W. Baird dropped their price target on Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Leerink Partners raised their price target on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the stock a “market perform” rating in a research note on Tuesday. Stifel Nicolaus dropped their price objective on shares of Inspire Medical Systems from $210.00 to $170.00 and set a “hold” rating for the company in a research note on Monday, June 24th. KeyCorp decreased their target price on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Finally, Bank of America cut their price target on Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating for the company in a report on Monday, June 3rd. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $214.85.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds have recently made changes to their positions in INSP. SouthState Corp purchased a new stake in Inspire Medical Systems in the second quarter valued at approximately $27,000. Quarry LP raised its holdings in shares of Inspire Medical Systems by 105.4% in the 2nd quarter. Quarry LP now owns 343 shares of the company’s stock valued at $46,000 after buying an additional 176 shares during the period. Daiwa Securities Group Inc. acquired a new position in Inspire Medical Systems during the 2nd quarter worth about $53,000. Principal Securities Inc. acquired a new position in Inspire Medical Systems in the 4th quarter valued at about $54,000. Finally, Van ECK Associates Corp increased its stake in Inspire Medical Systems by 7.5% during the second quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock worth $138,000 after purchasing an additional 72 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.